

Cerox CV®

Cefuroxime Axetil + Clavulanic acid

Description

Cerox CV® is a combination of Cefuroxime Axetil and Clavulanic Acid. Cefuroxime is a bactericidal second generation cephalosporin antibiotics, which is effective against a wide range of gram-positive and gram-negative organisms including many beta-lactamase producing strains.

The Clavulanic acid in Cerox CV protects Cefuroxime from degradation by β -lactamase enzymes and effectively extends the spectrum to include many bacteria normally resistant to Cefuroxime and other beta-lactam antibiotics. Thus, Cerox CV possesses the distinctive properties of a broad spectrum antibiotic and a beta-lactamase inhibitor.

Indication and usage

- Pharyngitis and/or tonsillitis
- Acute bacterial otitis media
- Acute bacterial maxillary sinusitis
- Lower respiratory tract infections including pneumonia
- Acute bacterial exacerbations of chronic bronchitis and secondary bacterial infections of acute bronchitis
- Skin and Skin-Structure Infections
- Urinary tract infections
- Bone and Joint infections
- Gonorrhea: Uncomplicated and disseminated gonococcal infections
- Early Lyme disease (erythema migrans)
- Septicemia
- Meningitis
- Switch therapy (injectable to oral) after surgery when patient's condition is improved.

Dosage and administration

Adolescents and Adults (13 years and older)

Type of Infection	Total Daily Dosage	Dosage Frequency	Duration
Pharyngitis and/or tonsillitis	500 mg	250 mg 12 hourly	10 days
Acute bacterial maxillary sinusitis	500 mg	250 mg 12 hourly	10 days
Acute bacterial exacerbations of chronic bronchitis	500 mg or 1000 mg	250 mg or 500 mg 12 hourly	10 days
Secondary bacterial infections of acute bronchitis	500 mg or 1000 mg	250 mg or 500 mg 12 hourly	5-10 days
Uncomplicated skin and skin-structure infections	500 mg or 1000 mg	250 mg or 500 mg 12 hourly	10 days
Uncomplicated urinary tract infections	500 mg	250 mg 12 hourly	7-10 days
Uncomplicated gonorrhea	1,000 mg once daily	Single dose	
Early Lyme disease	1000 mg	500 mg 12 hourly	20 days
Acute otitis media	500 mg	250 mg 12 hourly	10 days
Acute bacterial maxillary sinusitis	500 mg	250 mg 12 hourly	10 days

Use in pregnancy and lactation

Pregnancy: Both Cefuroxime and Clavulanic acid are pregnancy category B.

Lactation: Cefuroxime is excreted in human milk; consideration should be given to discontinuing nursing temporarily during treatment with Cefuroxime.

Side effects

Generally Cefuroxime and Clavulanic acid are well tolerated. However, a few side effects like nausea, vomiting, diarrhea, abdominal discomfort or pain may occur. As with other broad-spectrum antibiotics, prolonged administration of Cefuroxime and Clavulanic acid combination may result in overgrowth of non-susceptible microorganisms. Rare side effects are renal dysfunction, anaphylaxis, angioedema, pruritis, rash and serum sickness like urticaria may appear.

Precautions

Cefuroxime should be given with caution to patients receiving concurrent treatment with potent diuretics because these diuretics are suspected of adversely affecting renal function. Cefuroxime, as with other broad-spectrum antibiotics, should be prescribed with caution in individuals with a history of colitis.

Contraindications

It is contraindicated in patients with known allergy to Cefuroxime and Clavulanic acid or to the cephalosporin group of antibiotics.

Drug interactions

Probenecid: Concomitant administration of probenecid with Cefuroxime increases the area under the serum concentration versus time curve by 50%. The peak serum Cefuroxime concentration after a 1.5-g single dose is greater when taken with 1 g of probenecid than without probenecid.

Antacids: Drugs that reduce gastric acidity may result in a lower bioavailability of Cefuroxime and Clavulanic acids compared with that of fasting state and tend to cancel the effect of postprandial absorption.

Oral contraceptives: In common with other antibiotics, Cefuroxime may affect the gut flora, leading to lower estrogen re absorption and reduced efficacy of combined oral estrogen/progesterone.

Pharmaceutical precautions

Cerox CV tablet and powder for suspension should be kept in a cool (15–30 °C) and dry place and protected from light.

Presentation

Cerox CV 250: Each film coated tablet contains Cefuroxime 250 mg as Cefuroxime Axetil USP and Clavulanic Acid 62.5 mg as diluted Potassium Clavulanate BP.

Cerox CV 500: Each film coated tablet contains Cefuroxime 500 mg as Cefuroxime Axetil USP and Clavulanic Acid 125 mg as diluted Potassium Clavulanate BP.

Packaging

Cerox CV 250: Carton of 12 Tablets in Alu-Alu blister.

Cerox CV 500: Carton of 08 Tablets in Alu-Alu blister.

® Registered Trade Mark



ACI Limited